Blueprint Medicines Corporation
BPMC
Xếp hạng trong cổ phiếu
#2350
Blueprint Medicines Corporation is a biopharmaceutical company dedicated to... Blueprint Medicines Corporation is a biopharmaceutical company dedicated to pioneering precision therapies. Its core mission involves developing innovative treatments for various cancers and specific blood disorders, specifically those identified by genomic markers. These efforts extend to patients both within the United States and across international markets. The company's robust pipeline includes several key therapies. AYVAKIT is being advanced for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors. They are also developing BLU-263, a potent, orally administered KIT inhibitor, designed for non-advanced forms of SM and other conditions involving mast cells. Fisogatinib, another orally potent inhibitor, is under development for hepatocellular carcinoma. GAVRETO is being developed to address RET fusion-positive non-small cell lung cancer (NSCLC), various altered solid tumors, and medullary thyroid carcinoma. Furthermore, BLU-701 and BLU-945 are in the pipeline for epidermal growth factor receptor (EGFR)-driven non-small-cell lung carcinoma, while BLU-451 targets NSCLC specifically in patients with EGFR exon 20 insertion mutations. The company's broader pipeline includes BLU-782 for fibrodysplasia ossificans progressiva, BLU-222 for cyclin E aberrant cancers, and BLU-852 for various advanced cancers. To expand its reach and capabilities, Blueprint Medicines has established collaboration and licensing agreements with several partners, including Clementia Pharmaceuticals, Proteovant Therapeutics, CStone Pharmaceuticals, Genentech, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., and Zai Lab (Shanghai) Co., Ltd. Founded in 2008, the company was initially known as Hoyle Pharmaceuticals, Inc., before rebranding to Blueprint Medicines Corporation in June 2011. Its headquarters are located in Cambridge, Massachusetts.
Giá cổ phiếu
$129.46
Đồng bộ lần cuối: 2025-07-18
Vốn hóa thị trường
$8.36B
Thay đổi (1 ngày)
0.00%
Thay đổi (1 năm)
0.00%
Quốc gia
US
Giao dịch Blueprint Medicines Corporation (BPMC)
Danh mục
Healthcare
Tỷ lệ P/S của Blueprint Medicines Corporation (BPMC)
Tỷ lệ P/S vào October 2026 TTM: 16.43
Theo các báo cáo tài chính và giá cổ phiếu mới nhất của Blueprint Medicines Corporation, tỷ lệ P/S hiện tại (TTM) là 16.43. Vào cuối năm 2023, công ty có P/S là 22.40.
Lịch sử tỷ lệ P/S của Blueprint Medicines Corporation từ 2013 đến 2026
Tỷ lệ P/S vào cuối mỗi năm
| Năm | Tỷ lệ P/S | Thay đổi |
|---|---|---|
| 2026 (TTM) | 16.43 | 52.57% |
| 2024 | 10.77 | -51.90% |
| 2023 | 22.40 | 74.91% |
| 2022 | 12.81 | -63.21% |
| 2021 | 34.81 | 351.72% |
| 2020 | 7.71 | -86.62% |
| 2019 | 57.61 | 8.45% |
| 2018 | 53.12 | -60.07% |
| 2017 | 133.01 | 379.04% |
| 2016 | 27.77 | -34.10% |
| 2015 | 42.13 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
Tỷ lệ P/S của các công ty tương tự hoặc đối thủ cạnh tranh
| Công ty | Tỷ lệ P/S | Chênh lệch Tỷ lệ P/S | Quốc gia |
|---|---|---|---|
| 10.02 | -39.01% |
US
|
|
| 40.55 | 146.79% |
US
|
|
| 3.96 | -75.89% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -38.25% |
NL
|
